Christopher J. Logothetis

This paper develops a germline polygenic score (PRSagg) to predict prostate cancer aggressiveness and validates it across multiple datasets.

This study identifies a prostate cancer-induced endothelial-to-osteoblast transition that creates an immunosuppressive bone tumor microenvironment, reducing the effectiveness of immune checkpoint therapy in bone metastatic castrate-resistant prostate cancer.

This study identifies molecular changes in bladder mucosa that initiate cancer, revealing inflammation's role and mutation patterns linked to early carcinogenesis.

The paper improves prostate cancer risk stratification across multiple ancestries using a new polygenic hazard score with additional SNPs, showing higher hazard ratios and positive predictive value for clinically significant prostate cancer.

This study improves a polygenic hazard score for prostate cancer by adding 120 SNPs, enhancing hazard ratios but not positive predictive value of PSA testing.